Inozyme Pharma Inc. (INZY) NASDAQ
$4.58 (0.07) (-1.50%)
Market Cap: $287.24M
As of 04/18/24 04:00 PM EDT. Market closed.
Inozyme Pharma Inc. (INZY)
NASDAQ
$4.58
(0.07) (-1.50%)
Market Cap: $287.24M
As of 04/18/24 04:00 PM EDT. Market closed.
Add to Portfolio
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical ... read more
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
60
URL
Address
.
PRICE CHART FOR INOZYME PHARMA INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$4.64
Previous Close
$4.65
Days Range
$4.57 - $4.82
52 week range
$2.69 - $7.80
Volume
561,269
Avg. Volume (30 days)
977,163
Market Cap
$287.24M
Dividend Yield
-
P/E
-
Shares Outstanding
61,771,977
Open
$4.64
Previous Close
$4.65
Days Range
$4.57 - $4.82
52 week range
$2.69 - $7.80
Volume
561,269
Avg. Volume (30 days)
977,163
Market Cap
$287.24M
Dividend Yield
-
P/E
-
Shares Outstanding
61,771,977
FINANCIAL STATEMENTS FOR INOZYME PHARMA INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR INOZYME PHARMA INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Treco Douglas A | CEO | Apr 02, 2024 | Sale | $6.94 | 7,523 | 52,210 | 20,665 | Apr 03, 2024, 05:23 PM |
| Winton Matthew | COO | Mar 28, 2024 | Option Exercise | $3.33 | 3,188 | 10,616 | 3,188 | Apr 03, 2024, 05:23 PM |
| Subramanian Sanjay | SVP, CFO | Sep 29, 2023 | Option Exercise | $3.57 | 2,319 | 8,279 | 30,398 | Oct 03, 2023, 04:05 PM |
| Pivotal bioVenture Partners Fund I, L.P. | Director | Aug 01, 2023 | Buy | $4.80 | 833,333 | 3,999,999 | 2,923,110 | Aug 03, 2023, 08:13 PM |
| Hopfner Robert Lorne | Director | Aug 01, 2023 | Buy | $4.80 | 833,333 | 3,999,999 | 2,923,110 | Aug 03, 2023, 08:01 PM |
| Hopfner Robert Lorne | Director | May 12, 2023 | Buy | $6.25 | 228,702 | 1,429,388 | 3,661,518 | May 15, 2023, 05:06 PM |
| Hopfner Robert Lorne | Director | May 11, 2023 | Buy | $6.48 | 219,230 | 1,420,610 | 3,432,816 | May 15, 2023, 05:06 PM |
| Bolte Axel | Director | Mar 31, 2023 | Option Exercise | $2.21 | 4,806 | 10,621 | 266,696 | Apr 04, 2023, 08:40 AM |
| Subramanian Sanjay | SVP, CFO | Mar 31, 2023 | Option Exercise | $2.21 | 979 | 2,164 | 28,079 | Apr 04, 2023, 08:37 AM |
| Hopfner Robert Lorne | Director | Mar 29, 2023 | Buy | $4.54 | 344,592 | 1,563,724 | 3,213,586 | Mar 30, 2023, 05:46 PM |
| Hopfner Robert Lorne | Director | Mar 27, 2023 | Buy | $3.70 | 51,074 | 188,729 | 2,712,228 | Mar 29, 2023, 07:30 PM |
| Hopfner Robert Lorne | Director | Mar 28, 2023 | Buy | $4.16 | 156,766 | 652,335 | 2,868,994 | Mar 29, 2023, 07:30 PM |
| Bjarke Henric Bjorn | SVP, COO | Dec 15, 2022 | Buy | $1.39 | 21,500 | 29,885 | 105,441 | Dec 19, 2022, 08:30 AM |
| Bolte Axel | Chief Executive Officer | Sep 30, 2022 | Option Exercise | $2.28 | 3,315 | 7,558 | 261,890 | Oct 04, 2022, 08:00 AM |
| Bjarke Henric Bjorn | SVP, COO | Sep 30, 2022 | Option Exercise | $2.28 | 3,315 | 7,558 | 83,941 | Oct 04, 2022, 08:00 AM |
| Longitude Capital Partners III, LLC | 10% Owner | Apr 19, 2022 | Buy | $3.69 | 1,355,000 | 4,999,950 | 4,174,379 | Apr 21, 2022, 06:04 PM |
| Pivotal bioVenture Partners Fund I, L.P. | Director | Apr 19, 2022 | Buy | $3.69 | 1,070,000 | 3,948,300 | 2,661,154 | Apr 20, 2022, 06:22 PM |
| Bjarke Henric Bjorn | SVP, COO | Apr 19, 2022 | Buy | $3.69 | 27,100 | 99,999 | 80,626 | Apr 20, 2022, 04:05 PM |
| Bolte Axel | Chief Executive Officer | Apr 19, 2022 | Buy | $3.69 | 67,750 | 249,998 | 258,575 | Apr 20, 2022, 04:05 PM |
| Hopfner Robert Lorne | Director | Apr 19, 2022 | Buy | $3.69 | 1,070,000 | 3,948,300 | 2,661,154 | Apr 20, 2022, 04:05 PM |
| Subramanian Sanjay | SVP, CFO | Apr 19, 2022 | Buy | $3.69 | 27,100 | 99,999 | 27,100 | Apr 20, 2022, 04:05 PM |
| Bolte Axel | Chief Executive Officer | Jun 24, 2021 | Option Exercise | $0.98 | 66,788 | 65,452 | 257,613 | Jun 25, 2021, 07:58 AM |
| Bolte Axel | Chief Executive Officer | Jun 24, 2021 | Sale | $0.00 | 66,788 | 7 | 190,825 | Jun 25, 2021, 07:58 AM |
| Novo Holdings A/S | 10% Owner | Jan 28, 2021 | Sale | $21.00 | 375,000 | 7,875,000 | 2,194,379 | Feb 01, 2021, 04:30 PM |
| Novo Holdings A/S | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 375,000 | 6,000,000 | 2,569,379 | Jul 29, 2020, 05:29 PM |
| Sanofi | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 81,250 | 1,300,000 | 520,125 | Jul 29, 2020, 06:06 AM |
| Rock Springs Capital Management LP | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 600,000 | 9,600,000 | 1,067,884 | Jul 28, 2020, 08:53 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 600,000 | 9,600,000 | 2,003,653 | Jul 28, 2020, 06:33 PM |
| Sonsini Peter W. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:30 PM |
| SANDELL SCOTT D | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:29 PM |
| MAKOWER JOSHUA | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:29 PM |
| Makhzoumi Mohamad | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:28 PM |
| Florence Anthony A. Jr. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:27 PM |
| BASKETT FOREST | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:26 PM |
| New Enterprise Associates 15, L.P. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 250,000 | 4,000,000 | 2,437,689 | Jul 28, 2020, 06:26 PM |
| Longitude Capital Partners III, LLC | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 625,000 | 10,000,000 | 2,819,379 | Jul 28, 2020, 06:20 PM |
| Pivotal bioVenture Partners Fund I, L.P. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 187,500 | 3,000,000 | 1,591,154 | Jul 28, 2020, 06:15 PM |
| Hopfner Robert Lorne | Director | Jul 28, 2020 | Buy | $16.00 | 187,500 | 3,000,000 | 1,591,154 | Jul 28, 2020, 06:11 PM |
| Sofinnova Venture Partners X, L.P. | 10% Owner | Jul 28, 2020 | Buy | $16.00 | 437,500 | 7,000,000 | 2,028,308 | Jul 28, 2020, 06:08 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
FUNDS WITH A POSITION IN INOZYME PHARMA INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,537,500 | 0.05% | No change | Other |
| BLACKROCK INC. | 3,042,330 | 0.00033% | 35.83% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,032,716 | 0.00046% | 25.51% | Other |
| UBS OCONNOR LLC | 244,928 | 0.08% | 57.71% | Value |
| RENAISSANCE TECHNOLOGIES LLC | 218,500 | 0.00144% | -26.08% | Other |
| AQR CAPITAL MANAGEMENT LLC | 45,913 | 0.00037% | 132.54% | Other |
| ALPS ADVISORS INC | 42,215 | 0.00141% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR INOZYME PHARMA INC
STOCK BUYBACKS FOR INOZYME PHARMA INC
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
9.01%
1Q
12/31/2022
41.31%
4Q
09/30/2022
41.73%
5Q
06/30/2022
55.84%
6Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR INOZYME PHARMA INC
LOADING...